Mathew Njoroge

Mathew Njoroge

Auto-generated profile, based on publicly available information

Mathew Njoroge

Holistic Drug Discovery and Development (H3D) Centre University of Cape Town Cape Town South Africa

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2014 in Chemical Reviews
Verified
Journal Article
Closed access
MNMathew Njoroge
Mathew Njoroge
NNNicholas M. Njuguna
Nicholas M. Njuguna
PMPeggoty Mutai
Peggoty Mutai
DODennis Ongarora
Dennis Ongarora
PSPaul W. Smith
Paul W. Smith
KCKelly Chibale
Kelly Chibale

20 November 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RWRenier van der Westhuyzen
Renier van der Westhuyzen
SWSusan Winks
Susan Winks
CWColin R. Wilson
Colin R. Wilson
GBGrant A. Boyle
Grant A. Boyle
RGRichard K. Gessner
Richard K. Gessner
KCKelly Chibale
Kelly Chibale

1 January 2014 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
FMFaith Mjambili
Faith Mjambili
MNMathew Njoroge
Mathew Njoroge
KNKrupa Naran
Krupa Naran
CKCarmen De Kock
Carmen De Kock
PSPeter J. Smith
Peter J. Smith
KCKelly Chibale
Kelly Chibale

15 August 2018 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
EYEuna Yoo
Euna Yoo
BSBarbara H. Stokes
Barbara H. Stokes
HJHanna de Jong
Hanna de Jong
MVManu Vanaerschot
Manu Vanaerschot
TKTrs Kumar
Trs Kumar
MBMatthew Bogyo
Matthew Bogyo

1 January 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RSRajni Kant Sharma
Rajni Kant Sharma
YYYassir Younis
Yassir Younis
GMGrace Mugumbate
Grace Mugumbate
MNMathew Njoroge
Mathew Njoroge
JGJiri Gut
Jiri Gut
KCKelly Chibale
Kelly Chibale

1 September 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
CBChristel Brunschwig
Christel Brunschwig
NLNina Lawrence
Nina Lawrence
DTDale Taylor
Dale Taylor
EAEfrem Abay
Efrem Abay
MNMathew Njoroge
Mathew Njoroge
KCKelly Chibale
Kelly Chibale
The 2-aminopyridine MMV048 was the first drug candidate inhibiting Plasmodium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical development. In an effort to identify the next generation of PI4K inhibitors, the series was optimized to improve properties such as solubility and antiplasmodial potency across the parasite lifecycle, leading to the 2-aminopyrazine UCT943. The compound displayed higher asexual blood stage, transmission-blocking, and liver stage activity than MMV048 and was more potent against resistant P. falciparum and P. vivax clinical isolates. Excellent in vitro antiplasmodial activity translated into high efficacy in P. berghei and humanized P. falciparum NOD-scid IL-2Rγnull mouse models. The high passive permeability and high aqueous solubility of UCT943, combined with low to moderate in vitro intrinsic clearance, resulted in sustained exposure and high bioavailability in preclinical species. In addition, the predicted human dose for a curative single administration using monkey and dog pharmacokinetics was low, ranging from 50 to 80 mg. As a next generation Plasmodium PI4K inhibitor, the combined preclinical data suggest that UCT943 has the potential to form part of a single-exposure radical cure and prophylaxis (SERCaP) to treat, prevent and block the transmission of malaria.